Disclosures: The authors report no relevant financial disclosures.
September 13, 2021
1 min read
Save

Coexistence of fatty liver disease, hypertension does not affect cardiovascular mortality

Disclosures: The authors report no relevant financial disclosures.
You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Regarding cardiovascular mortality, results published in the Scandinavian Journal of Gastroenterology demonstrated a negative interaction between fatty liver disease and hypertension in nondiabetic men.

"The relation between hypertension and fatty liver disease is still not fully understood. The two conditions are not mutually independent regarding their effect on cardiovascular disease and mortality, as was previously thought, but they affect each other, and likely they antagonize each other,” Mounir Ould Setti, Institute of Public Health and Clinical Nutrition, University of Eastern Finland, Kuopio, Finland, told Healio Gastroenterology. “The study is but an appetizer to the subject and further research is needed in the topic. Our findings should not, at this stage, suggest a change in clinical practice.”

Ould Setti and colleagues enrolled 1,569 middle-aged nondiabetic Finnish men from a population-based cohort and followed them for 34 years. They used Cox proportional hazards models to evaluate separate and combined effects of fatty liver disease and hypertension and their interaction at the multiplicative and additive scales regarding all-cause and cardiovascular death after adjusting for age, BMI, smoking and alcohol consumption.

Fatty liver disease and hypertension coexisted in 8.54% of the men, according to study results. Investigators noted hypertension independently and combined correlated with an increased hazard of all-cause and cardiovascular deaths. Ould Setti and colleagues noted non-cardiovascular mortality correlated with fatty liver disease; however, not with hypertension.

“We found a negative interaction between FLD and hypertension regarding the hazard of all-cause (relative excess risk due to interaction (RERI), 0.97; 95% [CI], 1.65 to 0.28) and CV mortality (RERI, 1.74; 95% CI, 2.98 to 0.5),” Ould Setti and colleagues wrote.

According to researchers, this interaction was observed on a multiplicative scale.